KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Interest Expenses (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Interest Expenses readings, the most recent being $14.1 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 42.19% to $14.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $78.9 million, a 19.94% decrease, with the full-year FY2025 number at $78.9 million, down 19.94% from a year prior.
  • Interest Expenses hit $14.1 million in Q4 2025 for Biocryst Pharmaceuticals, down from $19.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $28.9 million in Q2 2023 to a low of $12.9 million in Q1 2021.
  • Median Interest Expenses over the past 5 years was $24.2 million (2022), compared with a mean of $22.2 million.
  • Biggest five-year swings in Interest Expenses: surged 382.23% in 2021 and later plummeted 42.19% in 2025.
  • Biocryst Pharmaceuticals' Interest Expenses stood at $18.8 million in 2021, then soared by 40.88% to $26.5 million in 2022, then dropped by 7.09% to $24.6 million in 2023, then fell by 0.55% to $24.4 million in 2024, then plummeted by 42.19% to $14.1 million in 2025.
  • The last three reported values for Interest Expenses were $14.1 million (Q4 2025), $19.7 million (Q3 2025), and $21.6 million (Q2 2025) per Business Quant data.